Live Breaking News & Updates on Michael Leuchten

Stay updated with breaking news from Michael leuchten. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ozempic Maker Novo Rises After First Stock Split in a Decade

(Bloomberg) Novo Nordisk A/S shares fell on Wednesday in the first trading session following a split aimed at increasing the liquidity of the Danish drugmaker’s soaring stock.Most Read from BloombergLuxury Cruise Ship Full of Australians Stuck in Greenland ArcticiPhone Pro’s Titanium Finish Stands Out in First Look at DeviceChina Flags ‘Security Incidents’ With Apple’s iPhonesApple’s iPhone 15 Debut Includes Higher Price on Top ModelAT&T, T-Mobile Offer Free iPhone 15 in Lure for New Subscrib ....

United States , Bloomberg Businessweek , Nicolas Domont , Michael Leuchten , Bloomberg Novo Nordisk , Thomas Brenier , Richard Vosser , Health Care , Barclays Plc , Jpmorgan Chase Co , Eli Lilly Co , Novo Nordisk , American Depositary Receipts , Split Aims , Big Tech Like Retail Buzz , Emily Field , Eli Lilly , Lazard Freres Gestions , Novo Nordisk , American Depositary Receipts , Global Market , Obesity Drugs , Trading Session ,

ASTRAZENECA : UBS gives a Buy rating -Today at 07:25 am

In his latest research note, analyst Michael Leuchten confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price is unchanged and still at GBX 13000. ....

Michael Leuchten ,

ROCHE HOLDINGS AG : UBS gives a Neutral rating -Today at 08:13 am

Analyst Michael Leuchten from UBS research gives the stock a Neutral rating. The target price remains set at CHF 280. ....

Michael Leuchten , Analyst Michael Leuchten ,